Asahi Kasei Pharma received the 59th Annual Okochi Memorial Technology Prize for the development of a genetically-engineered thrombomodulin agent for the treatment of disseminated intravascular coagulation (DIC).
57th Annual Meeting of Thrombosis and Haemostasis Research
Presented by Dr. Inder Kaul, President of Product Development and Chief Medical Officer, Recognized for "Best Abstract Preis"
31 October, 2012
Asahi Kasei Pharma America Initiates Phase 3 Clinical Trial for ART-123 in Severe Sepsis Patients with Coagulopathy (US Release).
29 October, 2012
Initiation of a Global Phase III Clinical Trial for ART-123 (Japan Release)
Dysregulation of Inflammatory and Hemostatic Markers in Sepsis and Suspected Disseminated Intravascular Coagulation. Clinical and Applied Thrombosis/Hemostasis, 1076029613509476, November 19, 2013.
Thrombin generation mediators and markers in sepsis-associated coagulopathy and their modulation by recombinant thrombomodulin. Clinical and Applied Thrombosis/Hemostasis 2014, Vol 20(2) 129-135.
A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med. 2013 Sep;41(9):2069-79.
Asahi Kasei Pharma America (AKP America) is a biopharmaceutical company dedicated to bringing best-in-class critical care therapeutics to patients throughout the world. The company is a wholly-owned subsidiary of Asahi Kasei Pharma Corp.
ART 123 (recombinant human thrombomodulin alpha, marketed as Recomodulin® in Japan), our lead product candidate, represents a promising new treatment for severe sepsis with coagulopathy. This drug has successfully completed a Phase 2b clinical trial in disseminated intravascular coagulation (DIC) and Phase 3 trials will be underway shortly. This product might also be beneficial for a number of other indications.